The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Ironwood Pharmaceuticals Inc

Nasdaq: IRWD
Last

(U.S.) $15.51

Today's change0.00 0.00%
Updated December 2 4:00 PM EST. Delayed by at least 15 minutes.
 

Ironwood Pharmaceuticals Inc

Nasdaq: IRWD
Last

(U.S.) $15.51

Today's change0.00 0.00%
Updated December 2 4:00 PM EST. Delayed by at least 15 minutes.

Ironwood Pharmaceuticals Inc closed at (U.S.)$15.51.

Shares have lost 6.68% over the last five days, but have gained 33.82% over the last year to date. This security has outperformed the S&P 500 by 22.99% during the last year.

Key company metrics

  • Open(U.S.) $0.00
  • Previous close(U.S.) $15.51
  • High--
  • Low--
  • Bid / Ask(U.S.) $7.99 / (U.S.) $0.00
  • YTD % change+33.82%
  • Volume0
  • Average volume (10-day)1,237,039
  • Average volume (1-month)1,404,146
  • Average volume (3-month)1,280,075
  • 52-week range(U.S.) $7.35 to (U.S.) $16.89
  • Beta1.47
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$0.57
Updated December 2 4:00 PM EST. Delayed by at least 15 minutes.
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2016Q2/2016Q1/2016Q4/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201609/30/2016Jun 30, 201606/30/2016Mar 31, 201603/31/2016Dec 31, 201512/31/2015
Revenue66546653
Total other revenue--------
Total revenue66546653
Gross profit66546653
Total cost of revenue0000
Total operating expense94706859
Selling / general / administrative45373632
Research & development38323228
Depreciation / amortization31----
Interest expense (income), net operating--------
Unusual expense (income)90--0
Other operating expenses, total--------
Operating income-28-15-2-6
Interest income (expense), net non-operating-10-10-10-10
Gain (loss) on sale of assets--------
Other--------
Income before tax-33-22-13-14
Income after tax-33-22-13-14
Income tax, total--------
Net income-33-22-13-14
Total adjustments to net income--------
Net income before extra. items-33-22-13-14
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-33-22-13-14
Inc. avail. to common incl. extra. items-33-22-13-14
Diluted net income-33-22-13-14
Dilution adjustment--------
Diluted weighted average shares145145144143
Diluted EPS excluding extraordinary itemsvalue per share-0.23-0.15-0.09-0.10
Dividends per sharevalue per share0.000.000.00--
Diluted normalized EPSvalue per share-0.17-0.15-0.09-0.10